🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 84 of 857 · Phase 3 first, then by program name

  1. IXIARO

    Valneva Austria GmbH

    Japanese Encephalitis

    phase 3 mab completed

    1 trial

  2. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia (ITP)

    phase 3 mab active

    1 trial

  3. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia

    phase 3 mab active

    2 trials

  4. Iberdomide, Iberdomide, Dexamethasone 2mg Tablets , BORTEZOMIB, DARZALEX 1800 mg solution for injection, Dexamethason-ratiopharm® 4 mg Tabletten, Iberdomide, Iberdomide

    Celgene Europe Limited

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  5. Ibrutinib

    Janssen Cilag International NV

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  6. Ibrutinib hard capsule for oral use, Ibrutinib

    AbbVie Deutschland GmbH & Co. KG

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  7. Ibuprofen

    CUMBERLAND PHARMACEUTICALS INC

    Fever

    phase 3 small molecule completed

    2 trials

  8. Ibutamoren Mesylate, Ibutamoren Mesylate, Matched placebo capsules administered orally once per day, Ibutamoren Mesylate

    Lacuna Pharma Pty Ltd

    Growth Hormone Deficiency (GHD)

    phase 3 small molecule active

    1 trial

  9. Icatibant

    Takeda

    Angiotensin Converting Enzyme Inhibitor Induced Angioedema

    phase 3 small molecule completed

    1 trial

  10. Icatibant

    Takeda

    Angioedema

    phase 3 small molecule completed

    1 trial

  11. Icatibant

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    3 trials

  12. Iclepertin

    Boehringer Ingelheim

    Schizophrenia

    phase 3 small molecule terminated

    2 trials

  13. Icosapent (MND-2119)

    Mochida Pharmaceutical Company,

    Hypertriglyceridemia

    phase 3 small molecule completed

    1 trial

  14. Icotrokinra

    Janssen Cilag International NV

    Crohn Disease

    phase 3 small molecule active

    1 trial

  15. Icotrokinra, JNJ-77242113-AAC Placebo tablet

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  16. Idefirix 11 mg powder for concentrate for solution for infusion

    Hansa Biopharma AB

    End stage chronic kidney disease (CKD) patients who are highly sensitised and on the kidney transplant list awaiting a kidney transplant

    phase 3 small molecule active

    1 trial

  17. Identical to NBI-1065845 tablets without active drug, NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  18. Identical to kai-9531 solution for injection without active drug, KAI-9531, KAI-9531, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  19. Identical to the Test product, XGEVA 120 mg solution for injection

    Shanghai Reinovax Biologics Co.,LTD

    Prevention of breast cancer in women with a BRCA1 germline mutation

    phase 3 small molecule active

    1 trial

  20. Iduronate-2-sulfatase enzyme replacement therapy

    Takeda

    Mucopolysaccharidosis II

    phase 3 mab completed

    1 trial

  21. Idursulfase (idursulfase-IT [HGT-2310])

    Takeda

    Hunter Syndrome and Cognitive Impairment

    phase 3 small molecule active

    1 trial

  22. Ifinatamab deruxtecan, IRINOTECAN HYDROCHLORIDE, DOCETAXEL, PACLITAXEL

    Daiichi Sankyo

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 small molecule active

    1 trial

  23. IkT-001Pro, Placebo to match 100 mg IKT-001 tablets

    Inhibikase Therapeutics

    Pulmonary Arterial Hypertension

    phase 3 small molecule active

    1 trial

  24. Ilaprazole

    Yang Xiaotian

    Erosive Esophagitis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources